Alnylam’s Amvuttra To Take Off From Onpattro’s Runway
Most Onpattro Patients Expected To Switch
The company won approval in hATTR amyloidosis polyneuropathy for the RNAi drug, which offers quarterly subcutaneous dosing versus Onpattro’s I.V. administration every three weeks.
